Craft
  • Home
  •  / CymaBay Therapeutics
CymaBay Therapeutics

CymaBay Therapeutics

Market Capitalization

$299.7 M

2022-09-22

CymaBay Therapeutics Summary

Company summary

Overview
CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. The Company's two key clinical development candidates are Seladelpar and Arhalofenate. Seladelpar is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis and the epidemic in nonalcoholic SteatoHepatitis. Arhalofenate is a potential urate-lowering anti-flare therapy for gout that is Phase 3 ready. The Company's pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.
Type
Public
Founded
1991
HQ
Newark, CA, US | view all locations
Website
http://www.cymabay.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Sujal Shah

    Sujal Shah, President and Chief Executive Officer, Director

    • Robert J. Wills, Chairman

      • Klara Dickinson

        Klara Dickinson, Chief Regulatory and Quality Assurance Officer

        • Janet Dorling

          Janet Dorling, Director

          LocationsView all

          1 location detected

          • Newark, CA HQ

            United States

            7575 Gateway Blvd #110

          CymaBay Therapeutics Financials

          Summary financials

          Net income (Q2, 2022)
          ($27.1M)
          Cash (Q2, 2022)
          $52.8M
          EBIT (Q2, 2022)
          ($23.8M)
          Enterprise value
          $248.0M

          Footer menu